Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

St. Vincent's Hospital Sydney Pty Ltd. provides health services. It offers cardiology, dental, endocrinology, audiology, mental health, medicine, sacred heart health services, urology, and vascular surgery. The company was founded in 1857 and is headquartered in Darlinghurst, Australia.

SphingoTec is a biomaker company that develops and markets in vitro diagnostic solutions for novel and proprietary blood-based protein biomarkers. They also develop microtiter plates, which are a standard tool in analytical research and diagnostic testing laboratories. They develop biomakers to address diagnostically underserved critical care conditions such as acute kidney injury, sepsis, and acute heart failure.

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases. In pulmonology, they are focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease. Pirfenidone, the only medicine approved for IPF anywhere in the world, is approved for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.

Critical Diagnostics is a company on the cutting edge of this change, focused on the discovery, development, and commercialization of novel biomarkers in cardiovascular diseases. Their lead product, the Presage® ST2 Assay, has received FDA clearance and is CE Marked in Europe. This simple, non-invasive test measures for soluble ST2 in the blood, which can aid physicians in risk assessment of heart failure patients. Soluble ST2 has now been published in more than 100 peer-reviewed articles and scientific posters studying more than 36,000 patients. These clinical studies have demonstrated that high levels of soluble ST2 are predictive of adverse patient outcomes and death in a broad spectrum of cardiovascular disease. They have further shown that the prognostic information from soluble ST2 is independent and provides added information to the cardiac biomarkers commonly used today, including the natriuretic peptides, BNP and NT-proBNP. Critical Diagnostics was founded in 2004. The Company licensed intellectual property discovered in 2002 at Brigham and Women's Hospital relating to ST2, for which it now holds the exclusive worldwide rights. The company has since expanded its intellectual property portfolio and holds several issued patents in the US and abroad as well as numerous patents pending.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Part of University of Arkansas System, Board of Trustees of The University of Arkansas is a company headquartered in Fayetteville, AR, that owns and operates radio stations.

CORTEX Biophysik GmbH manufactures and markets medical devices. Its products include Metamax 3B, Metalyzer 3B, meta control 3000, Metaswim and metasoft studio. The company was founded in 1991 and is headquartered in Leipzig, Germany.

Cardiac Pacemakers, Inc.(CPI), doing business as Guidant Cardiac Rhythm Management, manufactured implantable cardiac rhythm management devices, such as pacemakers and defibrillators. It also sold insulin pumps controlled by microprocessors and various equipments to regulate heart rhythm. In addition, Cardiac Pacemakers, Inc. developed therapies for the treatment of irregular heartbeats. The company was founded in 1971 and is based in St. Paul, Minnesota. Cardiac Pacemakers, Inc. operates as a subsidiary of Boston Scientific Corporation.

Sirius Genomics, Inc. develops DNA-based diagnostic and pharmacogenetic products. Its product is Sepsis. It also develops companion diagnostics, that are closely tied to therapeutic decisions, leading to better patient outcomes through personalized medicine. Sirius generates value by improving the safety and effectiveness of pharmaceutical compounds. The company correlates patient genetics with clinical outcomes, leading to proprietary and commercially viable CDx products. Sirius Genomics was founded by James A. Russell and Keith Walley in 2001 and is headquartered in Vancouver, Canada.

AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.

Fresenius Medical Care North America is a hospital and health care company that focuses on providing healthcare services to people with renal and other chronic conditions. It offers dialysis facilities, outpatient cardiac and vascular labs, and urgent care centers. Fresenius Medical Care North America (FMCNA) is one of the largest providers of dialysis products and services. It has raised a record amount of money to support the goals and initiatives of the National Kidney Foundation (NKF) over the course of a two-year partnership. Fresenius Medical Care North America was founded in 1996 by Bill Valle and it is headquartered in Waltham, Massachusetts.

BIOMEDICA Medizinprodukte GmbH engages in the supply of medical devices and other goods. It also provides in vitro diagnostics for allergies, autoimmune diseases, endocrinology, gastroenterology, microbiology, and infectious diseases. In addition, the firm offers patient data management systems for the continuous electronic data monitoring of patients, which also allows the access of information from every department in the health facility. The company was founded in 1978 and is headquartered in Vienna, Austria.

Fu Wai Hospital, founded in 1956.

The Binding Site Group Ltd. engages in the development of medical equipment. It provides specialist diagnostic products to clinicians and laboratory professionals worldwide. Its products include freelite and hevylite; analysers and software; immunoassays; and manufacturing components. The company was founded by Jo Bradwell in 1983 and is headquartered in Birmingham, the United Kingdom.

Sanofi is a global healthcare company. Among their duties are researching disease causes, determining starting points for drug treatment, developing drugs, producing active ingredients, and delivering finished drugs and active ingredients. Specialists in vaccines, rare diseases, rare blood disorders, neurology, immunology, oncology, diabetes, cardiovascular diseases, and consumer healthcare.

Peking Union Medical College Hospital, also known as Beijing Xiehe Hospital (Chinese: 北京协和医院), is a renowned general hospital in Beijing, China. It was founded in 1921 by Rockefeller Foundation and is affiliated to both Peking Union Medical College (PUMC) and Chinese Academy of Medical Sciences (CAMS). During the Cultural Revolution, it was renamed the "Anti-imperialist Hospital".

BioMerieux designs, develops, manufactures, and markets in vitro diagnostic systems for clinical and industrial applications. The company’s diagnostic systems consist of reagents and consumables used to conduct biological tests, for use in performing screening, diagnostic assistance, prognosis, and treatment monitoring; instruments, platforms, and autoanalyzers used for automated testing at high or low throughputs; software to process analyses and systems to interpret biological test results; and other related services such as the installation and maintenance of instruments, user training, and the audit of laboratory workflows. BioMerieux offers diagnostic systems for clinical applications including the diagnosis of infectious diseases, comprising HIV, tuberculosis, and respiratory diseases, as well as cardiovascular diseases and targeted cancers based on the analysis of biological samples such as blood, saliva, and urine; and for industrial applications including the analysis of microbiological manufacturing such as food, pharmaceuticals, and cosmetics. The company markets and sells its products through a network of distributors to private sector analysis laboratories, hospital laboratories, blood banks, and physician office laboratories; food, pharmaceutical, and cosmetics industries; and independent quality control laboratories. It has operations in Europe, the Middle East, Africa, North America, Asia-Pacific, and Latin America. BioMerieux were founded in 1963 and is headquartered in Marcy l’Etoile, France. It is a subsidiary of Institut Mérieux.